Literature DB >> 9371609

Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

E Jurkiewicz1, G Hunsmann, J Schäffner, T Nisslein, W Lüke, H Petry.   

Abstract

The sequence variability of viral structure polypeptides has been associated with immune escape mechanisms. The V1 region of simian immunodeficiency virus (SIV) is a highly variable region of the SIVmac env gene. Here, we describe the V1 region as a linear neutralizing epitope. V1 region-specific neutralizing antibodies (NAb) were first demonstrated in a rabbit infected with a recombinant vaccinia virus carrying the env gene of human immunodeficiency virus type 2 strain ben (HIV-2ben). Since we detected in this animal V1 region-specific NAb that were able to neutralize not only human immunodeficiency virus type 2 but also SIVmac32H, we investigated whether a similar immune response is evoked in macaques (Macaca mulatta) either infected with SIVmac or immunized with the external glycoprotein (gp130) of the same virus. Distinctly lower NAb titers were found in the SIVmac-infected animals than in the gp130-immunized macaques. Since the NAb titers in both groups were high enough for competition experiments, we used five overlapping peptides encompassing the whole V1 region for a detailed identification of the epitope. In each of the 12 macaques investigated, we detected a high level of NAb reacting with at least one peptide located in the central part of the V1 region. The relatively high degree of divergence, especially within the central part of the V1 region, which characterized the evolution of the retroviral sequences from the original inoculum in the infected macaques suggests the development of escape mutants. Furthermore, 3 of 12 animals developed NAb directed against the amino-terminal end of the V1 region epitope. Sequence analysis, however, revealed relatively low levels of genetic drift and genetic variability within this part of the V1 region. The induction of V1 env-specific NAb not only in gp130-immunized macaques but also in SIVmac-infected animals in combination with the increased genetic variability of this region in vivo indicates a marked biological significance of this epitope for the virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371609      PMCID: PMC230253     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

Authors:  R Kikukawa; Y Koyanagi; S Harada; N Kobayashi; M Hatanaka; N Yamamoto
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.

Authors:  T J Palker; A J Muir; D E Spragion; H F Staats; A Langlois; D C Montefiori
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

3.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  Neutralizing antibodies and the course of HIV-induced disease.

Authors:  I Wendler; U Bienzle; G Hunsmann
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

5.  Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV).

Authors:  S Harada; D T Purtilo; Y Koyanagi; J Sonnabend; N Yamamoto
Journal:  J Immunol Methods       Date:  1986-09-27       Impact factor: 2.303

6.  Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

Authors:  M Robert-Guroff; K Aldrich; R Muldoon; T L Stern; G P Bansal; T J Matthews; P D Markham; R C Gallo; G Franchini
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

7.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Induction of anti-HIV neutralizing antibodies by synthetic peptides.

Authors:  T C Chanh; G R Dreesman; P Kanda; G P Linette; J T Sparrow; D D Ho; R C Kennedy
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  16 in total

1.  Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.

Authors:  H Petry; K Pekrun; G Hunsmann; E Jurkiewicz; W Lüke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain.

Authors:  Tahar Babas; Daniel Muñoz; Joseph L Mankowski; Patrick M Tarwater; Janice E Clements; M Christine Zink
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Authors:  Aravind Basavapathruni; Wendy W Yeh; Rory T Coffey; James B Whitney; Peter T Hraber; Ayush Giri; Bette T Korber; Srinivas S Rao; Gary J Nabel; John R Mascola; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

5.  Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.

Authors:  P Polacino; V Stallard; J E Klaniecki; D C Montefiori; A J Langlois; B A Richardson; J Overbaugh; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

6.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

7.  Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Authors:  M W Cho; Y B Kim; M K Lee; K C Gupta; W Ross; R Plishka; A Buckler-White; T Igarashi; T Theodore; R Byrum; C Kemp; D C Montefiori; M A Martin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses.

Authors:  Takeo Kuwata; Russell Byrum; Sonya Whitted; Robert Goeken; Alicia Buckler-White; Ronald Plishka; Ranjini Iyengar; Vanessa M Hirsch
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

9.  Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection.

Authors:  Kathryn M Kitrinos; Noah G Hoffman; Julie A E Nelson; Ronald Swanstrom
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.

Authors:  Brian J Rybarczyk; David Montefiori; Philip R Johnson; Ande West; Robert E Johnston; Ronald Swanstrom
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.